Impact of HIV infection and HAART on serum lipids in men
Open accessAbstract
CONTEXT: Alterations in serum lipid values have been widely reported among persons infected with human immunodeficiency virus (HIV) type 1 treated with highly active antiretroviral therapy (HAART), but no data have yet been reported on changes from preseroconversion lipid values. OBJECTIVE: To describe changes in serum cholesterol levels associated with HIV infection and antiretroviral medication exposure, and 1-time assessment of triglyceride levels post-HAART initiation. DESIGN, SETTING, AND PARTICIPANTS: The Multicenter AIDS Cohort Study, a prospective study in which homosexual and bisexual men were enrolled and from which 50 of 517 HIV seroconverters were drawn for the analysis herein, who later initiated HAART, involving measurements of stored serum samples obtained between 1984 and 2002. MAIN OUTCOME MEASURES: Changes in levels of total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) at 6 time points during an average of 12 years; 1-time assessment of triglyceride levels from the third post-HAART clinic visit. RESULTS: Among the 50 men, notable declines in mean serum TC (-30 mg/dL [-0.78 mmol/L]), HDL-C (-12 mg/dL [-0.31 mmol/L]), and LDL-C values (-22 mg/dL [-0.57 mmol/L]) were observed after HIV infection. Following HAART initiation, there were large increases in mean TC and LDL-C values (50 and 21 mg/dL [1.30 and 0.54 mmol/L], respectively); however, the mean changes from the preseroconversion values were 20 mg/dL (0.52 mmol/L) (95% confidence interval [CI], -1 to 41) and -1 mg/dL (-0.03 mmol/L) (95% CI, -25 to 22), respectively. Mean HDL-C remained below baseline levels throughout follow-up. The median value (interquartile range) of triglycerides was 225 mg/dL (2.54 mmol/L) (147-331 mg/dL). CONCLUSIONS: Before treatment, HIV infection results in substantial decreases in serum TC, HDL-C, and LDL-C levels. Subsequent HAART initiation is associated with increases in TC and LDL-C but little change in HDL-C. Increases in TC and LDL-C observed after about 3 years of HAART possibly represent a return to preinfection serum lipid levels after accounting for expected age-related changes.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HIV-infected patients typically have low total cholesterol and LDL-C, low HDL-C and increased triglycerides.
“HIV-infected patients typically have low TC and LDL-C, as well as low HDL-C and increased TGs.430,431”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [430]
Cites
Grundy, S. M., Bilheimer, D. W., Chait, A., Clark, L. T., Denke, M. A., Havel, R. J., Hazzard, W. R., Hulley, S. B., Hunninghake, D. B., Kreisberg, R. A., et al. (1993) · JAMA · doi:10.1001/jama.269.23.3015 · Cited by 27,944 · see citing works
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011 · see citing works
Enzymatic determination of total serum cholesterol.
Allain, C. C., Poon, L. S., Chan, C. S. G., Richmond, W., & Fu, P. C. (1974) · Clinical Chemistry · doi:10.1093/clinchem/20.4.470 · Cited by 9,845 · see citing works
Carr, A., Samaras, K., Burton, S., Law, M. G., Freund, J., Chisholm, D. J., & Cooper, D. A. (1998) · AIDS · doi:10.1097/00002030-199807000-00003 · Cited by 2,364 · see citing works
Carr, A. D., Samaras, K., Þórisdóttir, A. S., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999) · The Lancet · doi:10.1016/s0140-6736(98)08468-2 · Cited by 1,490 · see citing works
Warnick, G. R., & Albers, J. J. (1978) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)41577-9 · Cited by 1,250 · see citing works
Grünfeld, C., Pang, M., Doerrler, W. T., Shigenaga, J. K., Jensen, P., & Feingold, K. R. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.5.1373735 · Cited by 845 · see citing works
Bozzette, S. A., Ake, C. F., Tam, H. K., Chang, S. W., & Louis, T. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022048 · Cited by 626 · see citing works
Atherogenic Dyslipidemia in HIV-Infected Individuals Treated With Protease Inhibitors
Périard, D., Telenti, A., Sudre, P., Cheseaux, J., Halfon, P., Reymond, M. J., Marcovina, S. M., Glauser, M. P., NICOD, P. H., Darioli, R., et al. (1999) · Circulation · doi:10.1161/01.cir.100.7.700 · Cited by 603 · see citing works
Mulligan, K. M., Grünfeld, C., Tai, V., Algren, H. A., Pang, M., Chernoff, D., Lo, J. C.-M., & Schambelan, M. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200001010-00005 · Cited by 516 · see citing works
Behrens, G. M. N., Dejam, A., Schmidt, H., Balks, H. J., Brabant, G. E., Körner, T., Stoll, M., & Schmidt, R. E. (1999) · AIDS · doi:10.1097/00002030-199907090-00001 · Cited by 515 · see citing works
Severe premature coronary artery disease with protease inhibitors
Henry, K., Melroe, H., Huebsch, J. A., Hermundson, J., Levine, C., Swensen, L., & Daley, J. (1998) · The Lancet · doi:10.1016/s0140-6736(05)79053-x · Cited by 509 · see citing works
Johnson, C. L. (1993) · JAMA · doi:10.1001/jama.269.23.3002 · Cited by 469 · see citing works
Metabolic Disturbances and Wasting in the Acquired Immunodeficiency Syndrome
Flier, J. S., Underhill, L. H., Grunfeld, C., & Feingold, K. R. (1992) · New England Journal of Medicine · doi:10.1056/nejm199207303270506 · Cited by 398 · see citing works
Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome
Grünfeld, C., Kotler, D. P., Shigenaga, J. K., Doerrler, W. T., Tierney, A. R., Wang, J., Pierson, R. N., & Feingold, K. R. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)80154-e · Cited by 286 · see citing works
Circulating interferon-α levels and hypertriglyceridemia in the acquired immunodeficiency syndrome.
Grunfeld, C., Kotler, D. P., Shigenaga, J. K., Doerrler, W., Tierney, A., Wang, J., Pierson, R. N., & Feingold, K. R. (1991) · The American Journal of Medicine · doi:10.1016/0002-9343(91)90536-7 · Cited by 286 · see citing works
Giorgi, J. V., Cheng, H.-L., Margolick, J. B., Bauer, K. D., Ferbas, J., Waxdal, M. J., Schmid, I., Hultin, L. E., Jackson, A. L., Park, L., et al. (1990) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(90)90096-9 · Cited by 232 · see citing works
Atorvastatin and gemfibrozil for protease-inhibitor-related lipid abnormalities
Henry, K., Melroe, H., Huebesch, J., Hermundson, J., & Simpson, J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)00022-1 · Cited by 204 · see citing works
Shor‐Posner, G., Basit, A., Lü, Y., Cabrejos, C., Chang, J., Fletcher, M., Mantero-Atienza, E., & Baum, M. K. (1993) · The American Journal of Medicine · doi:10.1016/0002-9343(93)90087-6 · Cited by 197 · see citing works
Dong, K. L., Bausserman, L., Flynn, M. M., Dickinson, B. P., Flanigan, T., Mileno, M. D., Tashima, K. T., & Carpenter, C. C. (1999) · PubMed · Cited by 133 · see citing works
Rifai, N., Iannotti, E., DeAngelis, K. M., & Law, T. (1998) · Clinical Chemistry · doi:10.1093/clinchem/44.6.1242 · Cited by 109 · see citing works
Influence of protease inhibitor therapy on lipoprotein metabolism
Berthold, H. K., Parhofer, K. G., Ritter, M. M., Addo, M. M., Wasmuth, J., Schliefer, K., Spengler, U., & Rockstroh, J. K. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00615.x · Cited by 83 · see citing works
Roberts, A. D., Muesing, R. A., Parenti, D. M., Hsia, J., Wasserman, A. G., & Simon, G. L. (1999) · Clinical Infectious Diseases · doi:10.1086/520231 · Cited by 44 · see citing works
Bonnet, F., s, M. S., Droz‐Perroteau, C., et al. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00042560-200010010-00017 · Cited by 27 · see citing works
Bonnet, F., Savès, M., Droz, C., et al. (2000) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/00126334-200010010-00017 · Cited by 15 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162 · see citing works
Triant, V. A., Lee, H., Hadigan, C., & Grinspoon, S. K. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-2190 · Cited by 1,613 · see citing works
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.08.018 · Cited by 1,582 · see citing works
Class of Antiretroviral Drugs and the Risk of Myocardial Infarction
(2007) · New England Journal of Medicine · doi:10.1056/nejmoa062744 · Cited by 1,521 · see citing works
Fihn, S. D., Gardin, J. M., Abrams, J., Berra, K., Blankenship, J. C., Dallas, A. P., Douglas, P. S., Foody, J. M., Gerber, T. C., Hinderliter, A. L., et al. (2012) · Circulation · doi:10.1161/cir.0b013e318277d6a0 · Cited by 845 · see citing works
ESC/EAS Guidelines for the management of dyslipidaemias
Catapano, A. L., Reiner, Ž., De Backer, G., Graham, I., Taskinen, M.-R., Wiklund, O., Agewall, S., Alegria, E., Chapman, M. J., Durrington, P., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.06.028 · Cited by 706 · see citing works
Effros, R. B., Fletcher, C. V., Gebo, K., Halter, J. B., Hazzard, W. R., Horne, F. M., Huebner, R. E., Janoff, E. N., Justice, A. C., Kuritzkes, D., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/590150 · Cited by 539 · see citing works
The role of HIV in serious diseases other than AIDS.
Phillips, A. N., Neaton, J., & Lundgren, J. D. (2008) · AIDS · doi:10.1097/qad.0b013e3283174636 · Cited by 269 · see citing works
HIV infection and cardiovascular disease
Hemkens, L. G., & Bucher, H. C. (2014) · European Heart Journal · doi:10.1093/eurheartj/eht528 · Cited by 251 · see citing works
Metabolic syndrome, diabetes, and cardiovascular risk in HIV
Nix, L. M., & Tien, P. C. (2014) · Current HIV/AIDS Reports · doi:10.1007/s11904-014-0219-7 · Cited by 96 · see citing works
Jantarapakde, J., Phanuphak, N., Chaturawit, C., Pengnonyang, S., Mathajittiphan, P., Takamtha, P., Dungjun, N., Pinyakorn, S., Pima, W., Prasithsirikul, W., et al. (2014) · AIDS Patient Care and STDs · doi:10.1089/apc.2013.0294 · Cited by 84 · see citing works
Palella, F. J., Gange, S. J., Benning, L., Jacobson, L., Kaplan, R. C., Landay, A. L., Tracy, R. P., & Elion, R. (2010) · AIDS · doi:10.1097/qad.0b013e3283389dfa · Cited by 61 · see citing works
Cardiovascular disease risk in an aging HIV population: not just a question of biology
So-Armah, K., & Freiberg, M. S. (2014) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0000000000000065 · Cited by 45 · see citing works
- Authors
- Riddler, S. A.
- Affiliations
- University of Pittsburgh (US)
- Corresponding author
- Riddler, Sharon A.
- ORCID
- Riddler, Sharon A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2003-06-11
- Volume
- 289
- Issue
- 22
- Pages
- 2978
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2073738273
- Cited by
- 624
- References
- 25
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 15 · 2023: 17 · 2022: 15 · 2021: 25 · 2020: 11 · 2019: 24 · 2018: 20 · 2017: 20 · 2016: 32 · 2015: 28 · 2014: 41 · 2013: 38 · 2012: 38
- FWCI
- 25.40
- Type
- journal article
- Language
- en
- Open access
- green
- doi.org
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Abbott Laboratories
- Bristol-Myers Squibb
- Pfizer
- GlaxoSmithKline
- F. Hoffmann-La Roche
- Northwestern University
- Johns Hopkins University
- University of Pittsburgh
- Jaeb Center for Health Research
- National Institutes of Health (5r21de015166-02)
- University of California, Los Angeles
- Johns Hopkins Bloomberg School of Public Health
- National Institute of Allergy and Infectious Diseases (U01 AI 35039, U01AI035041, P01 AI-43664, U01AI046383, U01-AI-35041, U01AI035039, U01 AI46383, P01AI043664)
- National Institute of Dental and Craniofacial Research (DE 15166)
- Topics
- Health Sciences › Medicine › Emergency Medicine › HIV-related health complications and treatments
- Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Keywords
- HIV infection, highly active antiretroviral therapy, serum lipids, cholesterol, HDL cholesterol, LDL cholesterol, triglycerides, HIV seroconversion, men who have sex with men, Multicenter AIDS Cohort Study, HIV-associated dyslipidemia
- MeSH terms
- Adult, HIV Seropositivity, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Male, Regression Analysis, Triglycerides, HIV-1, HIV Infections, Anti-HIV Agents, Antiretroviral Therapy, Highly Active
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review